ARTL | tickerfilter.com

Fundamental analysis

41%

Profitability 35%

Dept financing 43%

Liquidity 26%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-11.82%

1 Month

-31.09%

3 Months

122.91%

6 Months

18.05%

1 Year

287.38%

2 Year

266.42%

Key data

Stock price

$3.99

P/E Ratio

0.00

DAY RANGE

$3.85 - $4.12

EPS

-$1.96

52 WEEK RANGE

$0.90 - $28.60

52 WEEK CHANGE

$283.65

MARKET CAP

2.463 M

YIELD

N/A

SHARES OUTSTANDING

2.125 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-12-2025

BETA

0.00

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$4,412,833

AVERAGE 30 VOLUME

$6,430,107

Company detail

CEO: Gregory D. Gorgas
Region: US
Website: artelobio.com
Employees: 5
IPO year: 2018

Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Artelo Biosciences, Inc. focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer. ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD.

ARTL - ARTELO BIOSCIENCES, INC.